Kinzalmono (Telmisartan)

Telmisartan is an angiotensin II receptor blocker indicated for conditions involving the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure in adults with essential hypertension.
• Cardiovascular risk reduction: helps reduce the risk of cardiovascular events in patients who cannot tolerate ACE inhibitors.
• Diabetic nephropathy: may delay progression of kidney disease in patients with type 2 diabetes and proteinuria.

• Telmisartan selectively antagonizes the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation. By blocking this pathway, it promotes vasodilation, reduces sodium and water retention, and ultimately lowers systemic vascular resistance and arterial pressure.

Telmisartan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: especially after the first dose or when standing up quickly.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Upper respiratory tract infection: nasopharyngitis.
• Diarrhea: loose stools without blood.
• Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects

• Hyperkalemia: elevated blood potassium levels.
• Acute kidney injury: sudden decline in renal function.
• Angioedema: swelling of face, lips, tongue, or throat.
• Liver enzyme elevation: increased transaminases.
• Severe hypotension: markedly low blood pressure, especially in volume‑depleted patients.

Before initiating telmisartan therapy, consider the following safety measures.

• Renal function: assess baseline creatinine and eGFR, adjust use in severe impairment.
• Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy: avoid use; teratogenic risk is unknown and may be harmful.
• Concomitant NSAIDs: use with caution as they may reduce antihypertensive effect and affect renal function.
• Volume depletion: ensure adequate hydration before starting therapy.
• Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture and direct sunlight.

Telmisartan can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients may increase risk of renal impairment, hyperkalemia, and hypotension.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: can raise lithium levels, risking toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and impair renal function.
• ACE inhibitors: concurrent use can increase risk of hypotension, hyperkalemia, and renal dysfunction.
• Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring.